Camurus AB has carried out a directed issue of approximately SEK 300 million
Camurus has carried out a directed issue to Swedish and international institutional investors raising approximately SEK 300 million through an accelerated book building process.
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of cancer, endocrine diseases, pain and addiction. Camurus’ shares are listed on Nasdaq Stockholm
Camurus was advised by Mannheimer Swartling in the transaction.
